• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

开发考虑混合模型中多峰参数分布的可视化预测检查。

Development of visual predictive checks accounting for multimodal parameter distributions in mixture models.

机构信息

Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden.

Faculty of Medicine and University Hospital Cologne, Center for Pharmacology, Department I of Pharmacology, University of Cologne, Gleueler Str 24, 50931, Cologne, Germany.

出版信息

J Pharmacokinet Pharmacodyn. 2019 Jun;46(3):241-250. doi: 10.1007/s10928-019-09632-9. Epub 2019 Apr 9.

DOI:10.1007/s10928-019-09632-9
PMID:30968312
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6560505/
Abstract

The assumption of interindividual variability being unimodally distributed in nonlinear mixed effects models does not hold when the population under study displays multimodal parameter distributions. Mixture models allow the identification of parameters characteristic to a subpopulation by describing these multimodalities. Visual predictive check (VPC) is a standard simulation based diagnostic tool, but not yet adapted to account for multimodal parameter distributions. Mixture model analysis provides the probability for an individual to belong to a subpopulation (IP) and the most likely subpopulation for an individual to belong to (MIXEST). Using simulated data examples, two implementation strategies were followed to split the data into subpopulations for the development of mixture model specific VPCs. The first strategy splits the observed and simulated data according to the MIXEST assignment. A shortcoming of the MIXEST-based allocation strategy was a biased allocation towards the dominating subpopulation. This shortcoming was avoided by splitting observed and simulated data according to the IP assignment. For illustration purpose, the approaches were also applied to an irinotecan mixture model demonstrating 36% lower clearance of irinotecan metabolite (SN-38) in individuals with UGT1A1 homo/heterozygote versus wild-type genotype. VPCs with segregated subpopulations were helpful in identifying model misspecifications which were not evident with standard VPCs. The new tool provides an enhanced power of evaluation of mixture models.

摘要

当研究人群的参数分布呈多峰时,非线性混合效应模型中个体间变异呈单峰分布的假设不成立。混合模型通过描述这些多峰性来识别与亚群相关的参数。可视化预测检查(VPC)是一种标准的基于模拟的诊断工具,但尚未适应于多峰参数分布。混合模型分析提供了个体属于亚群的概率(IP)和个体最有可能属于的亚群(MIXEST)。使用模拟数据示例,遵循了两种实施策略将数据分为亚群,以开发特定于混合模型的 VPC。第一种策略是根据 MIXEST 分配将观察数据和模拟数据分开。基于 MIXEST 的分配策略的一个缺点是偏向于主导亚群的分配。通过根据 IP 分配将观察数据和模拟数据分开,可以避免这种缺点。出于说明目的,这些方法也应用于伊立替康混合模型,该模型表明,UGT1A1 同/杂合子与野生型基因型个体中伊立替康代谢物(SN-38)的清除率低 36%。带有隔离亚群的 VPC 有助于识别标准 VPC 不明显的模型误定。该新工具提供了增强混合模型评估的能力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/48cd/6560505/aff88ad7f3b3/10928_2019_9632_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/48cd/6560505/f759fde99198/10928_2019_9632_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/48cd/6560505/b8c47d29c997/10928_2019_9632_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/48cd/6560505/2c757eac382a/10928_2019_9632_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/48cd/6560505/be489959a6d8/10928_2019_9632_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/48cd/6560505/0875be3c49ed/10928_2019_9632_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/48cd/6560505/e048fe924305/10928_2019_9632_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/48cd/6560505/e69c6bbbbc8a/10928_2019_9632_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/48cd/6560505/aff88ad7f3b3/10928_2019_9632_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/48cd/6560505/f759fde99198/10928_2019_9632_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/48cd/6560505/b8c47d29c997/10928_2019_9632_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/48cd/6560505/2c757eac382a/10928_2019_9632_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/48cd/6560505/be489959a6d8/10928_2019_9632_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/48cd/6560505/0875be3c49ed/10928_2019_9632_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/48cd/6560505/e048fe924305/10928_2019_9632_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/48cd/6560505/e69c6bbbbc8a/10928_2019_9632_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/48cd/6560505/aff88ad7f3b3/10928_2019_9632_Fig8_HTML.jpg

相似文献

1
Development of visual predictive checks accounting for multimodal parameter distributions in mixture models.开发考虑混合模型中多峰参数分布的可视化预测检查。
J Pharmacokinet Pharmacodyn. 2019 Jun;46(3):241-250. doi: 10.1007/s10928-019-09632-9. Epub 2019 Apr 9.
2
Modeling subpopulations with the $MIXTURE subroutine in NONMEM: finding the individual probability of belonging to a subpopulation for the use in model analysis and improved decision making.使用NONMEM中的$MIXTURE子程序对亚组进行建模:确定个体属于亚组的概率以用于模型分析和改进决策制定。
AAPS J. 2009 Mar;11(1):148-54. doi: 10.1208/s12248-009-9093-4. Epub 2009 Mar 10.
3
Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models.用于诊断非线性混合效应模型的预测校正可视化预测检验。
AAPS J. 2011 Jun;13(2):143-51. doi: 10.1208/s12248-011-9255-z. Epub 2011 Feb 8.
4
Population pharmacokinetics of liposomal irinotecan in patients with cancer and exposure-safety analyses in patients with metastatic pancreatic cancer.癌症患者中脂质体伊立替康的群体药代动力学及转移性胰腺癌患者中的暴露-安全性分析。
CPT Pharmacometrics Syst Pharmacol. 2021 Dec;10(12):1550-1563. doi: 10.1002/psp4.12725. Epub 2021 Nov 20.
5
Visual Predictive Check in Models with Time-Varying Input Function.具有时变输入函数的模型中的可视化预测检查
AAPS J. 2015 Nov;17(6):1455-63. doi: 10.1208/s12248-015-9808-7. Epub 2015 Aug 12.
6
Integration of DNA sequencing with population pharmacokinetics to improve the prediction of irinotecan exposure in cancer patients.将 DNA 测序与群体药代动力学相结合,以改善对癌症患者伊立替康暴露的预测。
Br J Cancer. 2022 Mar;126(4):640-651. doi: 10.1038/s41416-021-01589-2. Epub 2021 Oct 26.
7
Pharmacokinetic and Pharmacogenetic Markers of Irinotecan Toxicity.伊立替康毒性的药代动力学和药物遗传学标志物。
Curr Med Chem. 2019;26(12):2085-2107. doi: 10.2174/0929867325666180622141101.
8
Mixture models and subpopulation classification: a pharmacokinetic simulation study and application to metoprolol CYP2D6 phenotype.混合模型与亚群分类:一项药代动力学模拟研究及其在美托洛尔CYP2D6表型中的应用
J Pharmacokinet Pharmacodyn. 2007 Apr;34(2):141-56. doi: 10.1007/s10928-006-9038-9. Epub 2006 Oct 12.
9
Integrated population pharmacokinetics of etirinotecan pegol and its four metabolites in cancer patients with solid tumors.在患有实体瘤的癌症患者中,伊立替康聚乙二醇及其四种代谢物的综合群体药代动力学。
Cancer Chemother Pharmacol. 2018 May;81(5):897-909. doi: 10.1007/s00280-018-3562-3. Epub 2018 Mar 21.
10
Effect of UGT1A1, CYP3A and CES Activities on the Pharmacokinetics of Irinotecan and its Metabolites in Patients with UGT1A1 Gene Polymorphisms.UGT1A1、CYP3A 和 CES 活性对 UGT1A1 基因多态性患者伊立替康及其代谢物药代动力学的影响。
Eur J Drug Metab Pharmacokinet. 2021 Mar;46(2):317-324. doi: 10.1007/s13318-021-00675-3. Epub 2021 Feb 23.

引用本文的文献

1
Characterization of exposure-Clinical Dementia Rating-Sum of Boxes relationship in subjects with early Alzheimer's disease from the aducanumab Phase 3 trials.在 aducanumab 三期临床试验中,对早期阿尔茨海默病患者的暴露-临床痴呆评定量表-总评分关系进行特征描述。
J Pharmacokinet Pharmacodyn. 2023 Feb;50(1):45-62. doi: 10.1007/s10928-022-09839-3. Epub 2023 Jan 4.
2
Pharmacometric modeling of drug adverse effects: an application of mixture models in schizophrenia spectrum disorder patients treated with clozapine.药物不良反应的药物代谢动力学建模:混合模型在氯氮平治疗精神分裂症谱系障碍患者中的应用。
J Pharmacokinet Pharmacodyn. 2023 Feb;50(1):21-31. doi: 10.1007/s10928-022-09833-9. Epub 2022 Nov 15.
3

本文引用的文献

1
A Population Pharmacokinetic Analysis Shows that Arylacetamide Deacetylase (AADAC) Gene Polymorphism and HIV Infection Affect the Exposure of Rifapentine.人群药代动力学分析显示芳基乙酰胺脱乙酰酶(AADAC)基因多态性和 HIV 感染会影响利福喷丁的暴露量。
Antimicrob Agents Chemother. 2019 Mar 27;63(4). doi: 10.1128/AAC.01964-18. Print 2019 Apr.
2
Characterization of changes in HbA1c in patients with and without secondary failure after metformin treatments by a population pharmacodynamic analysis using mixture models.通过使用混合模型的群体药效学分析,对二甲双胍治疗后有和无继发性失效患者的糖化血红蛋白(HbA1c)变化进行特征描述。
Drug Metab Pharmacokinet. 2018 Dec;33(6):264-269. doi: 10.1016/j.dmpk.2018.08.002. Epub 2018 Aug 16.
3
A Model-Informed Method for the Purpose of Precision Dosing of Isoniazid in Pulmonary Tuberculosis.
一种用于精准调整肺结核患者异烟肼剂量的模型指导方法。
Clin Pharmacokinet. 2021 Jul;60(7):943-953. doi: 10.1007/s40262-020-00971-2. Epub 2021 Feb 22.
4
Extension of Pharmacokinetic/Pharmacodynamic Time-Kill Studies To Include Lipopolysaccharide/Endotoxin Release from Escherichia coli Exposed to Cefuroxime.将药代动力学/药效学时间杀菌研究扩展到包括暴露于头孢呋辛的大肠杆菌中脂多糖/内毒素的释放。
Antimicrob Agents Chemother. 2020 Mar 24;64(4). doi: 10.1128/AAC.02070-19.
A Regression Approach to Visual Predictive Checks for Population Pharmacometric Models.
基于回归的群体药代动力学模型可视化预测核查方法。
CPT Pharmacometrics Syst Pharmacol. 2018 Oct;7(10):678-686. doi: 10.1002/psp4.12319. Epub 2018 Sep 10.
4
Model-Based Residual Post-Processing for Residual Model Identification.基于模型的残差后处理方法在残差模型辨识中的应用
AAPS J. 2018 Jul 2;20(5):81. doi: 10.1208/s12248-018-0240-7.
5
Population pharmacokinetic and pharmacodynamic properties of artesunate in patients with artemisinin sensitive and resistant infections in Southern Myanmar.缅甸南部青蒿素敏感和耐药感染患者青蒿琥酯的群体药代动力学和药效学特性。
Malar J. 2018 Mar 23;17(1):126. doi: 10.1186/s12936-018-2278-5.
6
A Mechanism-Based Population Pharmacokinetic Analysis Assessing the Feasibility of Efavirenz Dose Reduction to 400 mg in Pregnant Women.基于机制的群体药代动力学分析评估在孕妇中将依非韦伦剂量减少至 400mg 的可行性。
Clin Pharmacokinet. 2018 Nov;57(11):1421-1433. doi: 10.1007/s40262-018-0642-9.
7
Model Evaluation of Continuous Data Pharmacometric Models: Metrics and Graphics.连续数据药代动力学模型的模型评估:指标与图形
CPT Pharmacometrics Syst Pharmacol. 2017 Feb;6(2):87-109. doi: 10.1002/psp4.12161. Epub 2017 Feb 10.
8
Effect of diurnal variation, CYP2B6 genotype and age on the pharmacokinetics of nevirapine in African children.昼夜变化、CYP2B6基因分型及年龄对奈韦拉平在非洲儿童体内药代动力学的影响。
J Antimicrob Chemother. 2017 Jan;72(1):190-199. doi: 10.1093/jac/dkw388. Epub 2016 Oct 5.
9
Enhanced Method for Diagnosing Pharmacometric Models: Random Sampling from Conditional Distributions.增强型药代动力学模型诊断方法:条件分布的随机抽样。
Pharm Res. 2016 Dec;33(12):2979-2988. doi: 10.1007/s11095-016-2020-3. Epub 2016 Sep 7.
10
Brivaracetam Population Pharmacokinetics and Exposure-Response Modeling in Adult Subjects With Partial-Onset Seizures.布立西坦在部分性发作成年患者中的群体药代动力学及暴露-反应模型
J Clin Pharmacol. 2016 Dec;56(12):1591-1602. doi: 10.1002/jcph.761. Epub 2016 Jun 7.